Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease

Transfusion

Volumn 54, Issue 2, 2014, Pages 353-363

  Hannon, Muriel ^a   Lechanteur, Chantal ^a   Lucas, Sophie ^a   Somja, Joan ^a   Seidel, Laurence ^a   Belle, Ludovic ^a   Bruck, France ^a   Baudoux, Etienne ^a   Giet, Olivier ^a   Chantillon, Anne Marie ^a   Delvenne, Philippe ^a   Drion, Pierre ^a   Beguin, Yves ^a   Humblet Baron, Stéphanie ^a   Baron, Frédéric ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BLOOD COMPONENT REMOVAL; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOPHENOTYPING; MICE; MICE, INBRED NOD; MICE, SCID; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84893984660     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12279     Document Type: Article

References (44)

1. Baron F, Storb R,. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004; 26: 71-94.
2. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED,; the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
3. Riddell SR, Berger C, Murata M, Randolph S, Warren EH,. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-162.
4. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers ME, Mielcarek M, Maloney DG, Storb R,. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
5. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, Socié G, Nagler A, Rocha V, Mohty M,. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462-2468.
6. Socie G, Blazar BR,. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009; 114: 4327-4336.
7. Blazar BR, Murphy WJ, Abedi M,. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
8. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ,. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118: 4242-4249.
9. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socié G,. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852-1858.
10. Weiden PL, Storb R, Tsoi MS, Graham TC, Lerner KG, Thomas ED,. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol 1976; 116: 1212-1219.
11. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T,. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance [Review]. Immunol Rev 2001; 182: 18-32.
12. Tian L, Humblet-Baron S, Liston A,. Immune tolerance: are regulatory T cell subsets needed to explain suppression of autoimmunity? Bioessays 2012; 34: 569-575.
13. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD,. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
14. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL,. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196: 401-406.
15. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS,. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
16. Colonna L, Sega EI, Negrin RS,. Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17 (1 Suppl): S58-S62.
17. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J,. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120: 1479-1493.
18. Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J,. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 2011; 118: 5021-5030.
19. Lord JD, Hackman RC, Gooley TA, Wood BL, Moklebust AC, Hockenbery DM, Steinbach G, Ziegler SF, McDonald GB,. Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 486-496.
20. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L,. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107: 1717-1723.
21. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S,. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16: 907-914.
22. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF,. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
23. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, DeFor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE,. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
24. Bruck F, Belle L, Lechanteur C, de Leval L, Hannon M, Dubois S, Castermans E, Humblet-Baron S, Rahmouni S, Beguin Y, Briquet A, Baron F,. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy 2013; 15: 267-279.
25. Canavan JB, Afzali B, Scotta C, Fazekasova H, Edozie FC, Macdonald TT, Hernandez-Fuentes MP, Lombardi G, Lord GM,. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012; 119: e57-e66.
26. Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N, Gothot A, Vanbellighen JF, Herens C, Seidel L, Geenen V, Cheynier R, Beguin Y,. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008; 93: 240-247.
27. Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, Willems E, Gothot A, Vanbellinghen JF, Geenen V, Sandmaier BM, Storb R, Beguin Y, Baron F,. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica 2011; 96: 298-306.
28. Stockis J, Fink W, Francois V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Boon T, Coulie PG, Lucas S,. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol 2009; 39: 869-882.
29. Lucas S, van Baren N, de Smet C, Coulie PG,. Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples. Int J Cancer 2012; 130: 1960-1966.
30. Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, Bonyhadi ML, Berenson RJ, Prior JL, Piwnica-Worms D, Nolta JA, DiPersio JF,. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol 2007; 35: 1823-1838.
31. Edinger M, Hoffmann P,. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011; 23: 679-684.
32. Humblet-Baron S, Baron F, Liston A,. Regulatory T cells fulfil their promise? Immunol Cell Biol 2011; 89: 825-826.
33. Tresoldi E, Dell'Albani I, Stabilini A, Jofra T, Valle A, Gagliani N, Bondanza A, Roncarolo MG, Battaglia M,. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica 2011; 96: 1357-1365.
34. Long SA, Buckner JH,. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 2008; 30: 293-302.
35. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orso E, Andreesen R, Holler E, Edinger M,. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006; 12: 267-274.
36. Di IM, Del PB, Cecchini D, Bonifacio E, Moretti L, Zei T, Ostini RI, Falzetti F, Fontana L, Tagliapietra G, Maldini C, Martelli MF, Tabilio A,. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clin Exp Immunol 2009; 156: 246-253.
37. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS,. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011; 118: 2342-2350.
38. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, III, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ,. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.
39. Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB,. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/-immunodeficient mice. Clin Cancer Res 2006; 12: 5520-5525.
40. Vercoulen Y, Guichelaar T, Meerding J, Emmelot M, Pingen M, Storm G, Coffer P, Sawitzki B, Martens A, Mutis T, Prakken B,. Application of cultured human regulatory T cells requires preclinical in vivo evaluation. J Allergy Clin Immunol 2012; 129: 852-855.
41. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR,. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 2011; 3: 83ra41.
42. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G,. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft versus host disease. Haematologica 2012; 98: 533-537.
43. Abraham S, Pahwa R, Ye C, Choi JG, Pahwa S, Jaggaiahgari S, Raut A, Chen S, Manjunath N, Shankar P,. Long-term engraftment of human natural T regulatory cells in NOD/SCID IL2rgammac(null) mice by expression of human IL-2. Plos ONE 2012; 7: e51832.
44. Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J,. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625-632.